P2-249: A Phase I Trial of ABT-751 and carboplatin in patients with previously treated non-small cell lung cancer

Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer

“…The recommended doses were 125 mg twice daily for 14 days for ABT-751 and an AUC of 6 on a 21-day cycle for carboplatin. Only seven patients were evaluated for activity, with two partial responses and four cases of stable disease, and the median TTP was 18.7 weeks [45] (Table 2). To date, ABT-751 is being evaluated as second-line therapy in combination with docetaxel or pemetrexed in two ran-domized, placebo-controlled phase II studies in patients with advanced NSCLC [44].…”

Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer

“…ABT-751, a microtubule-targeted agent, has also demonstrated antivascular properties [97]. A phase I trial evaluated ABT-751 with carboplatin [98]; the MTD of ABT-751 was 125 mg BID when administered for 14 days with carboplatin AUC 6 on Day 1 of a 21-day cycle (Day 4 of first cycle). Observed toxicities included thrombocytopenia, fatigue, neutropenia, constipation, and peripheral sensory neuropathy [98].…”

“…A phase I trial evaluated ABT-751 with carboplatin [98]; the MTD of ABT-751 was 125 mg BID when administered for 14 days with carboplatin AUC 6 on Day 1 of a 21-day cycle (Day 4 of first cycle). Observed toxicities included thrombocytopenia, fatigue, neutropenia, constipation, and peripheral sensory neuropathy [98]. A phase II study of ABT-751 200 mg/day as a single agent in patients with NSCLC has also been reported [99].…”